Review

Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety

Paul Ness*1, Michael Creer2, George M Rodgers3, Joseph J Naoum4, Kenneth Renkens5, Stacy A Voils6, W Allan Alexander7 for the Recognition, Evaluation and Treatment of Acquired Coagulopathy Consensus (RETACC) Panel

Address: 1Division of Hematology, Johns Hopkins Medicine, 600 North Wolfe Street, Carnegie 667, Baltimore, Maryland 21287, USA, 2Department of Pathology and Laboratory Medicine, St Louis University School of Medicine 1402 South Grand, St Louis, Missouri 63104, USA, 3Division of Hematology, University of Utah Health Sciences Center, 50 North Medical Center Drive, Salt Lake City, Utah 84132, USA, 4Division of Vascular Surgery, The Methodist Hospital, 6560 Fannin Street, Suite 1006, Houston, Texas, 77030 USA, 58402 Harcourt Road, Suite 400, Indianapolis, Indiana 46260, USA, 6Department of Pharmacy, Virginia Commonwealth University School of Pharmacy, 401 North 12th Street, PO Box 980042, Richmond, Virginia 23298-0042, USA and 7BioSurgery and Medical Affairs, ZymoGenetics, Inc, 1201 Eastlake Ave E, Seattle, Washington 98102, USA

Email: Paul Ness* - pness@jhmi.edu; Michael Creer - Creerm@slucare1.sluh.edu; George M Rodgers - george.rogers@hsc.utah.edu; Joseph J Naoum - JNaoum@tmhs.org; Kenneth Renkens - Krenkens@indianaspinegroup.com; Stacy A Voils - svoils@mcvh-vcu.edu; W Allan Alexander - alexanda@zgi.com; the Recognition, Evaluation and Treatment of Acquired Coagulopathy Consensus (RETACC) Panel - pness@jhmi.edu

* Corresponding author

Abstract

Topical hemostats, fibrin sealants, and surgical adhesives are regularly used in a variety of surgical procedures involving multiple disciplines. Generally, these adjuncts to surgical hemostasis are valuable means for improving wound visualization, reducing blood loss or adding tissue adherence; however, some of these agents are responsible for under-recognized adverse reactions and outcomes. Bovine thrombin, for example, is a topical hemostat with a long history of clinical application that is widely used alone or in combination with other hemostatic agents. Hematologists and coagulation experts are aware that these agents can lead to development of an immune-mediated coagulopathy (IMC). A paucity of data on the incidence of IMC contributes to under-recognition and leaves many surgeons unaware that this clinical entity, originating from normal immune responses to foreign antigen exposure, requires enhanced post-operative vigilance and judicious clinical judgment to achieve best outcomes.

Postoperative bleeding may result from issues such as loosened ties or clips or the occurrence of a coagulopathy due to hemodilution, vitamin K deficiency, disseminated intravascular coagulation (DIC) or post-transfusion, post-shock coagulopathic states. Other causes, such as liver disease, may be ruled out by a careful patient history and common pre-operative liver function tests. Less common are coagulopathies secondary to pathologic immune responses. Such coagulopathies include those that may result from inherent patient problems such as patients with an immune dysfunction related to systemic lupus erythematosus (SLE) or lymphoma that can invoke antibodies against native coagulation factors. Medical interventions may also provoke antibody
formation in the form of self-directed anti-coagulation factor antibodies, that result in problematic bleeding; it is these iatrogenic post-operative coagulopathies, including those associated with bovine thrombin exposure and its clinical context, that this panel was convened to address.

The RETACC panel’s goal was to attain a logical consensus by reviewing the scientific evidence surrounding IMC and to make recommendations for the clinical recognition, diagnosis and evaluation, and clinical management of these complications. In light of the under-recognition and under-reporting of IMC, and given the associated morbidity, utilization of health care resources, and potential economic impact to hospitals, the panel engaged in a detailed review of peer-reviewed reports of bovine thrombin associated IMC. From that clinical knowledge base, recommendations were developed to guide clinicians in the recognition, diagnosis, and management of this challenging condition.

Findings
Recognizing Immune-Mediated Coagulopathy Associated with Bovine Thrombin
IMC is thought to be a relatively uncommon, under-recognized, and iatrogenic medical condition that can result from exposure to non-human coagulation proteins, such as porcine FVIII and bovine thrombin [1,2]. Beginning in 1989, coincident with the rising utilization of bovine thrombin preparations for topical surgical hemostasis, a number of case reports of post-surgical bovine thrombin associated IMC began to appear in the literature [3-35]. IMC occurring unexpectedly in post-surgical patients who were either exposed or re-exposed to bovine thrombin preparations have continued to be reported in nearly all surgical specialties, though cardiac, pediatric and orthopedic/neurosurgical case reports comprise the majority (Table 1). Interestingly, in the panel’s literature review of 64 cases with known or presumed surgical exposure to topical bovine thrombin, there is a near equal representation of bleeding versus non-bleeding case presentations. Given that the majority of data on this condition is from case reports, the true incidence is unknown, but numerous reports have appeared in the literature since the year 2000 [3,6,7,11,17-19,22,24,25,27-29,31,36]. The true incidence of IMC associated with bovine thrombin remains unknown due to the lack of a clinical trial designed to answer that question. The result is a mixture of low awareness and confusion in the clinical community about the delayed onset of antibody formation and the challenges posed by masking due to coexistent coagulopathies (e.g., consumptive, dilutive, drug-induced, etc.).

This panel’s extensive review found that IMC always has a delayed onset following surgical procedures where bovine thrombin was used; none of the 61 cases reviewed (where time from exposure to clinical presentation was recorded), presented with symptoms or laboratory abnormalities earlier than 5 days following exposure (Table 2). The mean time to clinical presentation or laboratory abnormality (whichever was earlier) was 32 days, highlighting the potential for significant delay in onset and the potential for out of hospital risk. The most common time to presentation reported was 8 days (mode), while the median time to presentation was 11 days. Earlier clinical presentation in the 7 to 14 day time frame has most often been attributed to secondary exposure, where a second surgical exposure to a bovine thrombin preparation acts as a type of immunologic booster for antibody development [37,38]. Typically, primary exposure involves a more delayed clinical presentation due to the need for de novo maturation of the plasma B-cell antibody response. This obligatory time frame, dictated by the cellular and humoral mechanisms necessary for antibody formation, can delay diagnosis or even conceal the occurrence of these events from the surgeons employing these agents. The panel subscribe that with a proper index of suspicion,

Table 1: Reports of bleeding and non-bleeding IMC

|                | Bleeding Cases | Non-Bleeding Cases | Total† |
|----------------|----------------|--------------------|--------|
| Cardiac        | 21             | 19                 | 40     |
| Ortho/Neurosurgery | 5              | 5                  | 10     |
| Others         | 6              | 8                  | 14     |

† Pediatric cardiac cases accounted for 9 of the reported cardiac cases
Number of patients who presented with bleeding or laboratory abnormality among 64 cases that contained reports of a surgical setting where known or presumed bovine thrombin exposure occurred [3-35].
the resulting delays in recognition and treatment are preventable as are the increased morbidity, mortality, increased length of hospitalization and increased utilization of blood products that accompany this acquired disorder.

The evidence indicates that bovine thrombin related IMC results from antibodies that develop in response to bovine thrombin exposure and its associated proteins such as bovine factor V [18,31,39-41]. Bovine thrombin preparations have been reported to have in addition to bovine thrombin, bovine factors V, IX, and X as well as non-specific, immunoreactive proteins presumed to be protein fragments [42]. These antibodies may cross-react with human coagulation proteins, significantly interfering with the normal clotting cascade. Clinical sequelae range from individuals with abnormal prothrombin time (PT), activated partial thromboplastin time (aPTT) and thrombin time (TT) who are asymptomatic and at risk for bleeding [18,25,29,31] to anaphylaxis [36], hemorrhage [19,27], or other critical adverse events [17,19,27,43,44]. Despite prolonged efforts to improve manufacturing methods and remove contaminating proteins [18,38,40,41,45], there is no clinical evidence that bovine thrombin antigenicity has been reduced.

Most severe bleeding episodes occur following repeated exposure to bovine thrombin [34,46] and although history and documented use are often the best indication of previous bovine thrombin exposure, charts or pharmacy records can be incomplete. Accordingly, due to the widespread use of bovine thrombin in many different types of surgery, prior exposure can be difficult to determine in some patients. Even if documentation of prior exposure is available, it is impossible to predict whether antibodies will form or clinical sequelae will result. However, when presented with a patient with difficult to explain coagulopathy, a history that includes previous bovine thrombin exposure or procedures where it was likely used should raise suspicion of the potential for IMC as an etiology.

**Evaluation and diagnosis**

IMC should be included in differential diagnosis when there is unexplained postoperative bleeding and/or hematoma, unexplained PT, aPTT or TT in the absence of bleeding, an exaggerated response to anticoagulants in the post-operative period, or bleeding unresponsive to conventional treatment. Whether caused by antibodies to factor V or thrombin, IMC following secondary exposure to bovine thrombin generally begins between 7 – 14 days after repeated exposure to bovine thrombin; in the cases reviewed by the panel no patient presented with laboratory or symptomatic IMC earlier than 5 days following exposure (Table 2). Thus, patients may be at risk for delayed post-operative bleeding, especially those who are hospitalized more than a week after surgery; complex post-surgical recovery is presumed to be a risk factor for a more severe bleeding presentation. In this review, the presence of cross-reacting antibodies to factor V accounted for over 85% (28/32) in both the bleeding cases as well as the cases presenting with laboratory abnormalities alone (Table 3). Patients presenting with laboratory abnormalities in the late post-operative period are at risk for spontaneous hemorrhage. Relatively asymptomatic coagulopathy in discharged patients may go unrecognized exposing them to the inherent hemorrhagic risks of an unrecognized bleeding disorder. Auto-directed antibodies can be persistent, extending over a period of months or years [6,8,31,43]. However, clinical presentation of IMC may occur 1 month or more after an initial bovine thrombin exposure [17,43]. With subsequent exposures, the appearance of antibodies, prolonged coagulation tests, and clinical complications can occur earlier, though no cases have been reported earlier than 5 days following re-exposure [46]. Therefore, bovine thrombin-

| Table 2: Time from bovine thrombin exposure to clinical presentation of IMC |
|-------------------------------------------------|
| Mean (days) | 32 |
| Median (days) | 11 |
| Mode (days) | 8 |
| Standard Dev (days) | 65.8 |
| 95% CI (days) | 25–49 |
| Range (days) | 5–365 |

Summary statistics from review of 61 cases where time from known or presumed exposure were documented [3-10,12-18,20-28,30-33].

| Bleeding Cases | Non-Bleeding Cases | Total |
|----------------|--------------------|-------|
| N = 32 | N = 32 | n (%) |
| Inhibitor Type | | |
| FIIa | 4 (13) | 4 (12) | 8 (12) |
| FV | 17 (53) | 15 (47) | 32 (50) |
| FIIa and FV | 11 (34) | 13 (41) | 24 (38) |

Sorted by clinical presentation and contained reports of a surgical setting where known or presumed bovine thrombin exposure occurred [3-35].
associated IMC should be suspected when there is unex-
pected post-operative bleeding that is not explained by
common causes of post-operative coagulopathy. It should
also be suspected for post-surgical patients who have
abnormal coagulation tests upon return for postoperative
follow-up, management of a surgical complication or
prior to another surgical procedure.

The first step in evaluation and diagnosis of IMC is to
measure PT and aPTT (Figure 1) [47]. If these tests are
abnormal, common causes for post-surgical coagulopathy
should be ruled out. These include surgical bleeding with
hemodilution, DIC, vitamin K deficiency, and thrombo-
cytopenia. In IMC, PT and aPTT will be persistently ele-
vated as other common causes of post-surgical
coagulopathy are eliminated. It should be noted that TT
using human thrombin reagents may not be a reliable
screening test and should not be used as a definitive deter-
mination of IMC. If IMC remains in the differential diag-
nosis after excluding other potential causes of acquired
coagulopathy, consultation with a hematologist who is an
expert in coagulation testing would be prudent.

**Figure 1**

**Diagnosis of immune-mediated coagulopathy (IMC).** In response to elevated PT/aPTT, IMC should be considered in
the differential diagnosis for post-operative coagulopathy. Assays to rule out common causes of coagulopathies and mixing
studies should be conducted. If the mixing study fails to correct, an inhibitor should be suspected. A hematology consult should
be requested and factor assays conducted to confirm the diagnosis. (PT = prothrombin time; PTT = activated partial thrombo-
plastin time; FFP = fresh frozen plasma).

Unexplained elevation in PT, aPTT, +/- bleeding event

Review history & treatments

Consider common causes

Additional workup

Yes

FFP or vitamin K corrects?

Corrected

Repeat PT, aPTT with plasma mixing study

No correction

- Consider immune-mediated coagulopathy (IMC)
- Consult Hematology
In the presence of elevated PT and aPTT, a plasma mixing study should be ordered along with other laboratory studies (i.e., D-dimer, fibrinogen). Ideally, these studies should be ordered as soon as prolonged PT and aPTT are observed and before intervention of any kind, including administration of blood products. The clotting time of a 1:1 mix of patient plasma with normal pooled plasma should be evaluated immediately and at 60 and 120 minutes after incubation at 37°C. If the mixing study fails to correct and the clotting time falls outside of the reference range, then an inhibitor such as an antibody to a coagulation factor should be suspected. It should be noted that a mixing study is relatively insensitive for the early detection of a factor V inhibitor due to potentially low antibody titer levels in the period immediately following antigen exposure. However, if the PT and aPTT continue to be prolonged in the absence of a negative mixing test, the PT and aPTT should be monitored daily in conjunction with repeated mixing studies in any actively bleeding patient.

If not already initiated, a hematology and/or blood bank consult as well as confirmatory testing should follow a positive result from the mixing study. Laboratory evaluation should include specific quantitative assays of factor V and factor V inhibitor, if available. Most laboratories can evaluate factor V levels, but specific factor V antibody assays are not readily available and must be specially performed. More than one factor may be inhibited, but the majority of bovine thrombin-associated IMC cases reported in the literature have been linked to the development of pathogenic factor V inhibitors [17,19,27,31,43]. Transfusion will confound more specific factor and inhibitor assays; therefore, before initiating therapy additional blood samples should be obtained for more specific, definitive testing. Necessary supportive care and treatment should not be delayed while awaiting results since factor assay results may not be available for several days.

Management of patients with an IMC

Management of patients with IMC may be challenging. While the following recommendations reflect the consensus reached by the panel, it is important to note that there is limited large-scale clinical evidence supporting these recommendations.

Patients can be divided into asymptomatic patients at risk for bleeding and actively bleeding patients. For the 25 cases involving non-bleeding (at risk) patients reviewed here, the most common interventions were prolonged hospitalization for observation, trials of FFP and vitamin K and in some cases immune-modulation with corticosteroids and/or intravenous immune globulin (IVIG) (Table 4). The panel supports some of these reported practices such as for the non-bleeding patient, vitamin K in conjunction with close observation is recommended.

| Category                  | Count | %   |
|---------------------------|-------|-----|
| Extended LOS              | 23    | 92.0%|
| Vit K                     | 9     | 36.0%|
| FFP                       | 8     | 32.0%|
| IVIG                      | 5     | 20.0%|
| Plasmapheresis            | 5     | 20.0%|
| Steroids                  | 4     | 16.0%|
| PLT                       | 1     | 4.0% |
| Chemotherapy              | 0     | 0.0% |
| RBC                       | 0     | 0.0% |

Table 4: Reports of resource utilization in non-bleeding patients with IMC

LOS – Length of stay; FFP – fresh frozen plasma; Vit K – vitamin K; IVIG – intravenous immune globulin; PLT – platelets; RBC – red blood cells

Interventions among the 25 non-bleeding patients for whom case reports contained documentation of managing immune-mediated coagulopathy [3-5,8,9,11,12,14,15,18,21,22,22-26,28-31,35].

These patients should also avoid elective surgery until laboratory values normalize. The management of asymptomatic patients is largely patient-specific since the risk of spontaneous bleeding will vary as it does for patients on therapeutic anticoagulant regimens. Therefore, it is advisable that clinicians use their best judgment as to when to intervene. For patients with a history of comorbidities that increase their risk for bleeding, immunosuppression (e.g., corticosteroid therapy) may be reasonable. Prophylactic therapy to prevent spontaneous bleeding has been used to treat conditions like acquired hemophilia [48]. However, if surgery is planned, prophylaxis with the platelet transfusions necessary to treat the effects of anti-factor V antibodies entails risk and there is no definitive data demonstrating efficacy of this approach in otherwise asymptomatic IMC patients. Patient counseling, surveillance for complications, as well as serial factor assays and PT/aPTT assays, should be continued for six to eight weeks post-discharge or until values normalize. While the antibodies may be long-lasting in some patients [46], case reports suggest that the majority of the measurable inhibitors will eventually resolve. Parenthetically, skin testing for bovine thrombin induced hypersensitivity is not a useful screening technique because IMC is an IgG-mediated phenomenon while skin testing typically measures IgE-mediated mast cell degranulation and delayed T-cell mediated immune activation. Importantly, the duration of risk for an anamnestic response upon re-exposure is
unknown, suggesting that re-exposure should be avoided and the patient counseled regarding bovine thrombin immunogenicity.

Similarly, the management of actively bleeding IMC patients is highly speculative and patient specific. In the 18 reviewed cases involving patients bleeding at the time of clinical presentation, the most common reported interventions were prolonged hospitalization for supportive care, blood product transfusion, and vitamin K (Table 5). In 44% (8/18) of the cases, one or more interventions aimed at immune modulation occurred. These interventions included high dose corticosteroids, IVIG, plasmapheresis and potent chemotherapeutic immune suppression (cyclophosphamide, vincristine, others). Clearly, supportive care and replacement therapy with blood products are recommended. Fresh frozen plasma (FFP) and platelets should be administered in an effort to supplement coagulation factors in the face of a coagulopathy and to overcome the inhibitor [49]. Platelets may be particularly useful since normal platelets have factor V in alpha granules that is protected from circulating inhibitors (anti-factor antibodies). The immune system has a large capacity for antibody production. In situations where bleeding persists, further interventions designed to reduce circulating antibody titer may be indicated. Plasma exchange will accelerate inhibitor clearance and factor V replacement [27]. However, plasmapheresis only removes circulating antibody present in the intravascular space. Thus, due to rapid reappearance of antibody in plasma following redistribution from the larger extravascular space, the benefits of plasmapheresis may be only transient and multiple procedures will likely be required due to continued antibody production. In order to maintain factor V levels, plasma is indicated as the replacement fluid for plasmapheresis. In addition, there are inherent risks associated with plasma exchange and vascular access may be difficult to achieve in bleeding patients. Immunosuppressive therapy such as steroids, cyclophosphamide, rituximab, or IVIG (except during plasmapheresis), may be beneficial [17,19,28,29,31,50]. However, immunosuppression may take weeks to work. Therefore, immunosuppression alone is not sufficient for patients who are actively bleeding and may work best in conjunction with FFP and platelets. Because recombinant FVIIa (rFVIIa) depends upon an intact common coagulation pathway, rFVIIa is not recommended for treatment of actively bleeding IMC patients [17,43]. These recommendations are based upon a review of many case reports and not clinical trials, which would be difficult in view of the inherent difficulty in designing a trial where estimates of incidence rate vary widely.

Once the patient has stopped bleeding, supportive care and follow-up should continue until antibodies resolve and PT/aPTT normalize. Further intervention may not be required once hemostasis is achieved and if no other surgical procedures are required. If the PT/aPTT is not resolving, a new mixing study and factor assays should be ordered. If the PT does not begin to normalize and the factor V level is not recovering and a risk of spontaneous hemorrhage remains, then immunosuppression with IVIG or steroids may be indicated. The risks of immunosuppression in the post-surgical patient should be carefully weighed. As with non-bleeding patients with IMC, post-hemorrhagic patients should be monitored until resolution of the inhibitor. In both asymptomatic and bleeding patients where bovine thrombin-associated IMC has been confirmed, patients should be counseled to avoid re-exposure to bovine thrombin due to the risk for an anamnestic (B-memory cell mediated) response. If further invasive procedures are planned, alternative topical hemostats should be considered.

### Conclusion

IMC is an iatrogenic and preventable medical condition that continues to cause patient morbidity and mortality. The panel’s goal was to develop the recommendations included in this brief communication as a means of helping clinicians recognize, diagnose, and manage patients with IMC. The diagnosis of IMC requires clinical awareness and early re-evaluation of patient history; serial PT/aPTT tests, mixing studies, and factor assays are essential.

| Category          | Count | %  |
|-------------------|-------|----|
| Extended LOS      | 18    | 100.0% |
| FFP               | 12    | 66.7%  |
| RBC               | 10    | 55.6%  |
| Vit K             | 10    | 55.6%  |
| Steroids          | 8     | 44.4%  |
| PLT               | 8     | 44.4%  |
| IVIG              | 7     | 38.9%  |
| Plasmapheresis    | 5     | 27.8%  |
| Chemotherapy      | 3     | 16.7%  |

LOS – Length of stay; FFP – fresh frozen plasma; Vit K – vitamin K; IVIG – intravenous immune globulin; PLT – platelets; RBC – red blood cells

Interventions among the 18 bleeding patients for whom case reports contained documentation of managing immune-mediated coagulopathy [6,7,9,10,15-17,20,23,26,27,30,31,33,34].
for the definitive diagnosis of this condition. While supportive care is largely patient specific, a number of management options are available including replacement transfusion, platelets, plasmapheresis, and immunosuppression. IMC is an avoidable condition and alternatives to bovine thrombin should be considered in patients with a history of unexplained post-operative bleeding. Avoiding the use of bovine thrombin preparations altogether would likely reduce the risk of bovine thrombin-associated IMC, thus avoiding the morbidity and extensive hospital resource utilization that are associated with this difficult to diagnose and manage condition.

Competing interests
The RETACC panel acknowledges support from ZymoGenetics, Inc in facilitating the discussion of bovine thrombin-induced coagulopathy. The support allowed for the organization of a meeting for panel discussion and assistance with preparation and publication of the panel's recommendations.

Authors' contributions
All authors contributed equally to the development of the manuscript and its revisions.

Acknowledgements
We thank Michaela Ryan, PhD for editorial assistance, supported by ZymoGenetics, Inc.

References
1. Lawson JH: The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006, 32(Suppl 1):98-110.
2. Hay CR: Porcine factor VIII: past, present and future. Haematologica 2000, 85:21-24.
3. Adams JD, Jones S, Brost BC: Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J Reprod Med 2001, 46:909-912.
4. Banninger H, Hardegger T, Tobler A, Barth A, Schupbach P, Reinhart W, Lammle B, Furlan M: Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993, 85:528-532.
5. Berruyer M, Amiral J, Ffrench P, Belleville J, Bastien O, Clerc J, Kassir A, Estanove S, Dechavanne M: Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg 1993, 105:892-897.
6. Boshkov LK, Thomas G, Reller M, Roberts C, Shen I: Bleeding due to acquired antibody to factor V followed by stroke associated with high titer anticardiolipin (ACLA) antibody in a 14 month old congenital cardiac patient exposed to topical bovine thrombin. Blood 2002, 100:A3902.
7. Caers J, Reekmans A, Jochmans K, Naegels S, Mana F, Urbain D, Reyntaert H: Factor V Inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer. Endoscopy 2003, 35:542-544.
8. Chouhan VD, De La Cadena RA, Nagaswami C, Weisel JW, Kajani M, Rao AK: Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 1997, 77:343-349.
9. Christie RJ, Carrington L, Alving B: Postoperative bleeding induced by topical bovine thrombin: report of two cases. Surgery 1997, 121:708-710.
10. Cmolik BL, Spero J A, Magovern GJ, Clark RE: Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg 1993, 105:222-227.
11. Crow SS, Sullivan VV, Aysola AE, Key NS, Harker-Murray P, Foker JE, Steiner ME: Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg 2007, 83:1547-1549.
12. Cruickshank MK, Black J, Wall W: Development of a factor V and thrombin inhibitor following partial hepatic resection and the use of topical thrombin concentrate. Clin Lab Haematol 1994, 16:187-190.
13. Devez-Martín J, Sikkink RA, Gilchrist GS, Bowie EJ, Fass DN: Development of anti-bovine thrombin antibodies following neurosurgical procedures. Br J Haematol 1990, 74:369-370.
14. Flaherty MJ, Henderson R, Wener MH: Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin induced factor V deficiency. Blood 2004, 103:227-228.
15. Israels SJ, Israels ED: Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol 1994, 16:249-254.
16. Kajitani M, Ozdemir A, Akguna M, Zajeeh AR, Flick JT, Antaki T: Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 2000, 15:378-382.
17. Kapoor A, Cortese Hassel AL, Bontempo FA: Lack of Response Bleeding from Acquired Factor V Inhibitor to Recombinant Human Factor Vlla Concentrate. Blood 2005, 106:4099.
18. Lawson JH, Lynn KA, Vanmatre RM, Domazalski T, Klemp KF, Ortel TL, Niklasson LE, Parker W: Antithrombin factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 2005, 79:1037-1038.
19. Lewis B, Devreese K, Bossche J van den, Malfait R: Factor V inhibitor: case report. Blood Coagul Fibrinolysis 2006, 17:585-587.
20. Muntean W, Zenz W, Edlinger G, Beitzke A: Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin. Thromb Haemost 1997, 77:1223.
21. Muntean W, Zenz W, Finding K, Zobel G, Beitzke A: Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr 1994, 83:84-87.
22. Nesvick DG, Hejman MR, CheAnnechi V, Benjamin ME, Flinn WR: Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin. J Vasc Surg 2002, 35:400-402.
23. Ortel TL, Charles LA, Keller FG, Marcom PK, Oldham HN Jr, Kane WH, Mack BG: Topical thrombin and acquired factor V inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994, 45:128-135.
24. Pavlovich CP, Battiwalla M, Rick ME, Walther MM: Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy. J Urol 2001, 165:1617.
25. Peyton AR, Nelson MC, McCance SE, Levine RL, O’Leary PF: Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases. Spine 2003, 28:E221-223.
26. Rapaport SI, Zivelin A, Minow RA, Hunter CS, Donnelly K: Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992, 97:84-91.
27. Sarfati MR, Dilonore DJ, Kraiss LW, Galt SW: Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 2004, 18:349-351.
28. Savage WJ, Kicler T, Takemoto CM: Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer 2007, 49:1025-1029.
29. Shah AK, Moreno-Aspicita A: Acquired factor V inhibitor and single exposure to autologous growth factor. Thromb Res 2005, 116:87-89.
30. Spero JA: Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 1992, 78:817-820.
31. Streiff MB, Ness PM: Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002, 42:18-26.
32. Stricker RB, Lane PK, Leffert JD, Rodgers GM, Shuman MA, Corash L: Development of antithrombin antibodies following sur-
surgery in patients with prosthetic cardiac valves. Blood 1988, 72:1375-1380.
33. Tarantino MD, Ross MP, Daniels TM, Nichols WVL: Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 1997, 19:226-231.
34. Zehnder JL, Leung LL: Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990, 76:2011-2016.
35. Zumbrun MS, Waples JM, Kao KJ, Lottenberg R: Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant. Am J Hematol 2000, 64:59-63.
36. Wai Y, Tsai V, Peng Z, Richardson R, Oreopoulos D, Tarlo SM: Anaphylaxis from topical bovine thrombin (Thrombostat) during haemodialysis and evaluation of sensitization among a dialysis population. Clin Exp Allergy 2003, 33:1730-1734.
37. Schoenecker JG, Hauck RK, Mercer MC, Parker W, Lawson JH: Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha-1-3 galactose. J Clin Immunol 2000, 20:434-444.
38. Schoenecker JG, Johnson RK, Fields RC, Lesher AP, Domzalski T, Baig K, Lawson JH, Parker W: Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg 2003, 197:580-590.
39. Chapman WC, Singla N, Genyk Y, McNel JW, Renkens KL Jr, Reynolds TC, Murphy A, Weaver FA: A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007, 205:256-265.
40. Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J: Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 2008, 24:785-794.
41. Weaver FA, Lew W, Granke K, Yonehiro D, Delange B, Alexander WA: A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg 2008, 47:1266-1273.
42. Dorion RP, Hamati HF, Landis B, Frey C, Heydt D, Carey D: Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 1998, 122:887-894.
43. Kirkeby KM, Aronowitz P: Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application. Am J Med 2005, 118:805.
44. La Spada AR, Stalhegg BS, Henderson R, Schmer G, Pierce R, Chandler W: Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Engl J Med 1995, 333:494-497.
45. Terrab A, Pawlak D, Spasy P, Hoppensteadt D, Fareed J: Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost 2008, 14:135-140.
46. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH: Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001, 233:88-96.
47. Kamal AH, Tefferi A, Pruthi RK: How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007, 82:864-873.
48. Zeidler H, Ulrich-Merzenich G, Goldmann G, Vidovic N, Brackmann HH, Oldenburg J: The relevance of the bleeding severity in the treatment of acquired haemophilia – an update of a single-centre experience with 67 patients. Haemophilia 2008 in press.
49. Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, Bowie EJ: Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986, 77:405-415.
50. Lebrun A, Leroy-Matheron C, Arlet JB, Bartolucci P, Michel M: Successful treatment with rituximab in a patient with an acquired factor V inhibitor. Am J Hematol 2008, 83:163-164.